Table 3.
FMT studies in HSCT recipients for the treatment of GVHD.
| Study | Indication/Population | Number of Patients | Administration Route | Study Type | Donor Relation | Total Number of FMTs | Adverse Events | Response |
|---|---|---|---|---|---|---|---|---|
| Kakihana et al. [76] | Steroid resistant/dependent gut GVHD | 4 | Nasogastric tube | Prospective | Spouse /relative | 7 | 1- lower GI bleeding, hypoxemia (probably not related) | n = 3, CR; n = 1, PR |
| Spindelboeck et al. [78] | Steroid resistant grade IV gut GVHD | 3 | Colonoscopy | Retrospective, case series | Unrelated/sibling | 9 | No serious AEs | n = 2, CR; n = 1, PR |
| Qi et al. (NCT03148743) [79] | Steroid-resistant GvHD | 8 | Nasoduodenal tube | Prospective | Unrelated | 12 | No serious AEs | n = 5, CR; n = 1, PR |
| Shouval et al. (NCT 03214289) [81] | Steroid-resistant/dependent GVHD | 7 | Oral capsules | Prospective | Unrelated | 15 | 2-Bacteremia (deemed unrelated) | n = 2, CR |
| van Lier et al. [80] | Steroid-resistant/dependent GVHD | 15 | Nasoduodenal tube | Prospective | Unrelated | 15 | No serious AEs | n = 11, CR |
Abbreviation: FMT: Fecal microbiota transplantation, HSCT: Hematopoietic stem cell transplantation, GVHD: Graft-versus-host disease, CR: Complete response, PR: Partial response, AE: Adverse event.